Paraoxonase-1 Q192R Polymorphism and Antiplatelet Effects of Clopidogrel in Patients Undergoing Elective Coronary Stent Placement | Zendy

Dietmar Trenk | Zendy; Willibald Hochholzer | Zendy; Martin F. Fromm | Zendy; Oliver Zolk | Zendy; Christian Valina | Zendy; Christian Stratz | Zendy; FranzJosef Neumann | Zendy

Open Access

Paraoxonase-1 Q192R Polymorphism and Antiplatelet Effects of Clopidogrel in Patients Undergoing Elective Coronary Stent Placement

Author(s) -

Dietmar Trenk,

Willibald Hochholzer,

Martin F. Fromm,

Oliver Zolk,

Christian Valina,

Christian Stratz,

FranzJosef Neumann

Publication year - 2011

Publication title -

circulation cardiovascular genetics

Language(s) - English

Resource type - Journals

eISSN - 1942-325X

pISSN - 1942-3268

DOI - 10.1161/circgenetics.111.960112

Subject(s) - clopidogrel , medicine , coronary stent , pon1 , paraoxonase , cardiology , polymorphism (computer science) , stent , ticlopidine , myocardial infarction , genotype , biology , genetics , oxidative stress , restenosis , gene

Recently published data indicate that the paraoxonase-1 (PON1) Q192R genotype-and not as previously shown activity of cytochrome P450 (CYP) 2C19-is the major determinant of metabolic bioactivation of clopidogrel and thereby variability of antiplatelet effect of clopidogrel. We sought to investigate whether the PON1 Q192R gene polymorphism affects platelet reactivity in patients undergoing elective coronary stent placement.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research